Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma

Robert J. Motzer, Konstantin Penkov, John Haanen, Brian Rini, Laurence Albiges, Matthew T. Campbell, Balaji Venugopal, Christian Kollmannsberger, Sylvie Negrier, Motohide Uemura, Jae L. Lee, Aleksandr Vasiliev, Wilson H. Miller, Howard Gurney, Manuela Schmidinger, James Larkin, Michael B. Atkins, Jens Bedke, Boris Alekseev, Jing Wang & 8 others Mariangela Mariani, Paul B. Robbins, Aleksander Chudnovsky, Camilla Fowst, Subramanian Hariharan, Bo Huang, Alessandra Di Pietro, Toni K. Choueiri

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Background: In a single-group, phase 1b trial, avelumab plus axitinib resulted in objective responses in patients with advanced renal-cell carcinoma. This phase 3 trial involving previously untreated patients with advanced renal-cell carcinoma compared avelumab plus axitinib with the standard-of-care sunitinib. Methods: We randomly assigned patients in a 1:1 ratio to receive avelumab (10 mg per kilogram of body weight) intravenously every 2 weeks plus axitinib (5 mg) orally twice daily or sunitinib (50 mg) orally once daily for 4 weeks (6-week cycle). The two independent primary end points were progression-free survival and overall survival among patients with programmed death ligand 1 (PD-L1)-positive tumors. A key secondary end point was progression-free survival in the overall population; other end points included objective response and safety. Results: A total of 886 patients were assigned to receive avelumab plus axitinib (442 patients) or sunitinib (444 patients). Among the 560 patients with PD-L1-positive tumors (63.2%), the median progression-free survival was 13.8 months with avelumab plus axitinib, as compared with 7.2 months with sunitinib (hazard ratio for disease progression or death, 0.61; 95% confidence interval [CI], 0.47 to 0.79; P0.001); in the overall population, the median progression-free survival was 13.8 months, as compared with 8.4 months (hazard ratio, 0.69; 95% CI, 0.56 to 0.84; P0.001). Among the patients with PD-L1-positive tumors, the objective response rate was 55.2% with avelumab plus axitinib and 25.5% with sunitinib; at a median follow-up for overall survival of 11.6 months and 10.7 months in the two groups, 37 patients and 44 patients had died, respectively. Adverse events during treatment occurred in 99.5% of patients in the avelumab-plus-axitinib group and in 99.3% of patients in the sunitinib group; these events were grade 3 or higher in 71.2% and 71.5% of the patients in the respective groups. Conclusions: Progression-free survival was significantly longer with avelumab plus axitinib than with sunitinib among patients who received these agents as first-line treatment for advanced renal-cell carcinoma.

LanguageEnglish
Pages1103-1115
Number of pages13
JournalNew England Journal of Medicine
Volume380
Issue number12
DOIs
Publication statusPublished - 21 Mar 2019

Fingerprint

Renal Cell Carcinoma
Disease-Free Survival
sunitinib
avelumab
axitinib
Ligands
Confidence Intervals
Neoplasms
Survival
Standard of Care
Population
Disease Progression

Cite this

Motzer, R. J., Penkov, K., Haanen, J., Rini, B., Albiges, L., Campbell, M. T., ... Choueiri, T. K. (2019). Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. New England Journal of Medicine, 380(12), 1103-1115. https://doi.org/10.1056/NEJMoa1816047
Motzer, Robert J. ; Penkov, Konstantin ; Haanen, John ; Rini, Brian ; Albiges, Laurence ; Campbell, Matthew T. ; Venugopal, Balaji ; Kollmannsberger, Christian ; Negrier, Sylvie ; Uemura, Motohide ; Lee, Jae L. ; Vasiliev, Aleksandr ; Miller, Wilson H. ; Gurney, Howard ; Schmidinger, Manuela ; Larkin, James ; Atkins, Michael B. ; Bedke, Jens ; Alekseev, Boris ; Wang, Jing ; Mariani, Mariangela ; Robbins, Paul B. ; Chudnovsky, Aleksander ; Fowst, Camilla ; Hariharan, Subramanian ; Huang, Bo ; Di Pietro, Alessandra ; Choueiri, Toni K. / Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. In: New England Journal of Medicine. 2019 ; Vol. 380, No. 12. pp. 1103-1115.
@article{b379508a02624645b10f4d05531df2be,
title = "Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma",
abstract = "Background: In a single-group, phase 1b trial, avelumab plus axitinib resulted in objective responses in patients with advanced renal-cell carcinoma. This phase 3 trial involving previously untreated patients with advanced renal-cell carcinoma compared avelumab plus axitinib with the standard-of-care sunitinib. Methods: We randomly assigned patients in a 1:1 ratio to receive avelumab (10 mg per kilogram of body weight) intravenously every 2 weeks plus axitinib (5 mg) orally twice daily or sunitinib (50 mg) orally once daily for 4 weeks (6-week cycle). The two independent primary end points were progression-free survival and overall survival among patients with programmed death ligand 1 (PD-L1)-positive tumors. A key secondary end point was progression-free survival in the overall population; other end points included objective response and safety. Results: A total of 886 patients were assigned to receive avelumab plus axitinib (442 patients) or sunitinib (444 patients). Among the 560 patients with PD-L1-positive tumors (63.2{\%}), the median progression-free survival was 13.8 months with avelumab plus axitinib, as compared with 7.2 months with sunitinib (hazard ratio for disease progression or death, 0.61; 95{\%} confidence interval [CI], 0.47 to 0.79; P0.001); in the overall population, the median progression-free survival was 13.8 months, as compared with 8.4 months (hazard ratio, 0.69; 95{\%} CI, 0.56 to 0.84; P0.001). Among the patients with PD-L1-positive tumors, the objective response rate was 55.2{\%} with avelumab plus axitinib and 25.5{\%} with sunitinib; at a median follow-up for overall survival of 11.6 months and 10.7 months in the two groups, 37 patients and 44 patients had died, respectively. Adverse events during treatment occurred in 99.5{\%} of patients in the avelumab-plus-axitinib group and in 99.3{\%} of patients in the sunitinib group; these events were grade 3 or higher in 71.2{\%} and 71.5{\%} of the patients in the respective groups. Conclusions: Progression-free survival was significantly longer with avelumab plus axitinib than with sunitinib among patients who received these agents as first-line treatment for advanced renal-cell carcinoma.",
author = "Motzer, {Robert J.} and Konstantin Penkov and John Haanen and Brian Rini and Laurence Albiges and Campbell, {Matthew T.} and Balaji Venugopal and Christian Kollmannsberger and Sylvie Negrier and Motohide Uemura and Lee, {Jae L.} and Aleksandr Vasiliev and Miller, {Wilson H.} and Howard Gurney and Manuela Schmidinger and James Larkin and Atkins, {Michael B.} and Jens Bedke and Boris Alekseev and Jing Wang and Mariangela Mariani and Robbins, {Paul B.} and Aleksander Chudnovsky and Camilla Fowst and Subramanian Hariharan and Bo Huang and {Di Pietro}, Alessandra and Choueiri, {Toni K.}",
year = "2019",
month = "3",
day = "21",
doi = "10.1056/NEJMoa1816047",
language = "English",
volume = "380",
pages = "1103--1115",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "12",

}

Motzer, RJ, Penkov, K, Haanen, J, Rini, B, Albiges, L, Campbell, MT, Venugopal, B, Kollmannsberger, C, Negrier, S, Uemura, M, Lee, JL, Vasiliev, A, Miller, WH, Gurney, H, Schmidinger, M, Larkin, J, Atkins, MB, Bedke, J, Alekseev, B, Wang, J, Mariani, M, Robbins, PB, Chudnovsky, A, Fowst, C, Hariharan, S, Huang, B, Di Pietro, A & Choueiri, TK 2019, 'Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma' New England Journal of Medicine, vol. 380, no. 12, pp. 1103-1115. https://doi.org/10.1056/NEJMoa1816047

Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. / Motzer, Robert J.; Penkov, Konstantin; Haanen, John; Rini, Brian; Albiges, Laurence; Campbell, Matthew T.; Venugopal, Balaji; Kollmannsberger, Christian; Negrier, Sylvie; Uemura, Motohide; Lee, Jae L.; Vasiliev, Aleksandr; Miller, Wilson H.; Gurney, Howard; Schmidinger, Manuela; Larkin, James; Atkins, Michael B.; Bedke, Jens; Alekseev, Boris; Wang, Jing; Mariani, Mariangela; Robbins, Paul B.; Chudnovsky, Aleksander; Fowst, Camilla; Hariharan, Subramanian; Huang, Bo; Di Pietro, Alessandra; Choueiri, Toni K.

In: New England Journal of Medicine, Vol. 380, No. 12, 21.03.2019, p. 1103-1115.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma

AU - Motzer,Robert J.

AU - Penkov,Konstantin

AU - Haanen,John

AU - Rini,Brian

AU - Albiges,Laurence

AU - Campbell,Matthew T.

AU - Venugopal,Balaji

AU - Kollmannsberger,Christian

AU - Negrier,Sylvie

AU - Uemura,Motohide

AU - Lee,Jae L.

AU - Vasiliev,Aleksandr

AU - Miller,Wilson H.

AU - Gurney,Howard

AU - Schmidinger,Manuela

AU - Larkin,James

AU - Atkins,Michael B.

AU - Bedke,Jens

AU - Alekseev,Boris

AU - Wang,Jing

AU - Mariani,Mariangela

AU - Robbins,Paul B.

AU - Chudnovsky,Aleksander

AU - Fowst,Camilla

AU - Hariharan,Subramanian

AU - Huang,Bo

AU - Di Pietro,Alessandra

AU - Choueiri,Toni K.

PY - 2019/3/21

Y1 - 2019/3/21

N2 - Background: In a single-group, phase 1b trial, avelumab plus axitinib resulted in objective responses in patients with advanced renal-cell carcinoma. This phase 3 trial involving previously untreated patients with advanced renal-cell carcinoma compared avelumab plus axitinib with the standard-of-care sunitinib. Methods: We randomly assigned patients in a 1:1 ratio to receive avelumab (10 mg per kilogram of body weight) intravenously every 2 weeks plus axitinib (5 mg) orally twice daily or sunitinib (50 mg) orally once daily for 4 weeks (6-week cycle). The two independent primary end points were progression-free survival and overall survival among patients with programmed death ligand 1 (PD-L1)-positive tumors. A key secondary end point was progression-free survival in the overall population; other end points included objective response and safety. Results: A total of 886 patients were assigned to receive avelumab plus axitinib (442 patients) or sunitinib (444 patients). Among the 560 patients with PD-L1-positive tumors (63.2%), the median progression-free survival was 13.8 months with avelumab plus axitinib, as compared with 7.2 months with sunitinib (hazard ratio for disease progression or death, 0.61; 95% confidence interval [CI], 0.47 to 0.79; P0.001); in the overall population, the median progression-free survival was 13.8 months, as compared with 8.4 months (hazard ratio, 0.69; 95% CI, 0.56 to 0.84; P0.001). Among the patients with PD-L1-positive tumors, the objective response rate was 55.2% with avelumab plus axitinib and 25.5% with sunitinib; at a median follow-up for overall survival of 11.6 months and 10.7 months in the two groups, 37 patients and 44 patients had died, respectively. Adverse events during treatment occurred in 99.5% of patients in the avelumab-plus-axitinib group and in 99.3% of patients in the sunitinib group; these events were grade 3 or higher in 71.2% and 71.5% of the patients in the respective groups. Conclusions: Progression-free survival was significantly longer with avelumab plus axitinib than with sunitinib among patients who received these agents as first-line treatment for advanced renal-cell carcinoma.

AB - Background: In a single-group, phase 1b trial, avelumab plus axitinib resulted in objective responses in patients with advanced renal-cell carcinoma. This phase 3 trial involving previously untreated patients with advanced renal-cell carcinoma compared avelumab plus axitinib with the standard-of-care sunitinib. Methods: We randomly assigned patients in a 1:1 ratio to receive avelumab (10 mg per kilogram of body weight) intravenously every 2 weeks plus axitinib (5 mg) orally twice daily or sunitinib (50 mg) orally once daily for 4 weeks (6-week cycle). The two independent primary end points were progression-free survival and overall survival among patients with programmed death ligand 1 (PD-L1)-positive tumors. A key secondary end point was progression-free survival in the overall population; other end points included objective response and safety. Results: A total of 886 patients were assigned to receive avelumab plus axitinib (442 patients) or sunitinib (444 patients). Among the 560 patients with PD-L1-positive tumors (63.2%), the median progression-free survival was 13.8 months with avelumab plus axitinib, as compared with 7.2 months with sunitinib (hazard ratio for disease progression or death, 0.61; 95% confidence interval [CI], 0.47 to 0.79; P0.001); in the overall population, the median progression-free survival was 13.8 months, as compared with 8.4 months (hazard ratio, 0.69; 95% CI, 0.56 to 0.84; P0.001). Among the patients with PD-L1-positive tumors, the objective response rate was 55.2% with avelumab plus axitinib and 25.5% with sunitinib; at a median follow-up for overall survival of 11.6 months and 10.7 months in the two groups, 37 patients and 44 patients had died, respectively. Adverse events during treatment occurred in 99.5% of patients in the avelumab-plus-axitinib group and in 99.3% of patients in the sunitinib group; these events were grade 3 or higher in 71.2% and 71.5% of the patients in the respective groups. Conclusions: Progression-free survival was significantly longer with avelumab plus axitinib than with sunitinib among patients who received these agents as first-line treatment for advanced renal-cell carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=85062945683&partnerID=8YFLogxK

U2 - 10.1056/NEJMoa1816047

DO - 10.1056/NEJMoa1816047

M3 - Article

VL - 380

SP - 1103

EP - 1115

JO - New England Journal of Medicine

T2 - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 12

ER -

Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. New England Journal of Medicine. 2019 Mar 21;380(12):1103-1115. https://doi.org/10.1056/NEJMoa1816047